ロード中...
Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project
BACKGROUND: On 30 January 2012, the US FDA approved vismodegib (Erivedge(®), Genentech, CA, USA) for the management of both metastatic and locally advanced basal cell carcinoma. OBJECTIVE: Our objective was to identify evidence of hepatotoxicity with vismodegib in the FDA Adverse Event Reporting Sys...
保存先:
| 出版年: | Drugs R D |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer International Publishing
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5318336/ https://ncbi.nlm.nih.gov/pubmed/28063021 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-016-0168-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|